 Christopher Ford
Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 21 | 2024 | 286 | 5.700 |
Why?
| | Corpus Striatum | 12 | 2024 | 154 | 4.080 |
Why?
| | Receptors, Dopamine D2 | 12 | 2022 | 91 | 3.730 |
Why?
| | Cholinergic Neurons | 4 | 2019 | 16 | 2.290 |
Why?
| | Synaptic Transmission | 12 | 2023 | 275 | 2.130 |
Why?
| | Inhibitory Postsynaptic Potentials | 9 | 2016 | 40 | 2.090 |
Why?
| | Nucleus Accumbens | 6 | 2021 | 128 | 1.960 |
Why?
| | Neurons | 17 | 2021 | 1509 | 1.740 |
Why?
| | Substantia Nigra | 7 | 2023 | 55 | 1.470 |
Why?
| | Receptor, Muscarinic M4 | 2 | 2024 | 3 | 1.460 |
Why?
| | Dopaminergic Neurons | 7 | 2023 | 57 | 1.420 |
Why?
| | Synapses | 7 | 2024 | 397 | 1.410 |
Why?
| | Ventral Tegmental Area | 8 | 2023 | 52 | 1.300 |
Why?
| | Interneurons | 6 | 2021 | 120 | 1.230 |
Why?
| | Locus Coeruleus | 3 | 2022 | 21 | 1.070 |
Why?
| | Glutamic Acid | 4 | 2022 | 235 | 0.990 |
Why?
| | Ganglia, Sympathetic | 4 | 2008 | 14 | 0.950 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2024 | 12 | 0.930 |
Why?
| | Levodopa | 1 | 2024 | 30 | 0.920 |
Why?
| | Dynorphins | 2 | 2022 | 9 | 0.870 |
Why?
| | Receptors, Dopamine D1 | 2 | 2021 | 29 | 0.840 |
Why?
| | Parkinsonian Disorders | 2 | 2021 | 34 | 0.840 |
Why?
| | Neostriatum | 2 | 2021 | 33 | 0.810 |
Why?
| | Acetylcholine | 5 | 2024 | 184 | 0.810 |
Why?
| | Cholinergic Agents | 2 | 2019 | 15 | 0.800 |
Why?
| | Mice | 29 | 2024 | 16982 | 0.780 |
Why?
| | Neural Inhibition | 5 | 2009 | 157 | 0.750 |
Why?
| | Neurotransmitter Agents | 5 | 2023 | 81 | 0.750 |
Why?
| | Thalamus | 2 | 2021 | 100 | 0.750 |
Why?
| | Animals | 39 | 2024 | 35404 | 0.740 |
Why?
| | Parkinson Disease | 2 | 2024 | 462 | 0.720 |
Why?
| | Parasympathetic Nervous System | 1 | 2021 | 27 | 0.710 |
Why?
| | Motor Disorders | 1 | 2021 | 15 | 0.710 |
Why?
| | Signal Transduction | 7 | 2024 | 4935 | 0.680 |
Why?
| | Cocaine-Related Disorders | 1 | 2021 | 108 | 0.680 |
Why?
| | Cocaine | 2 | 2021 | 150 | 0.650 |
Why?
| | Action Potentials | 5 | 2019 | 485 | 0.650 |
Why?
| | Norepinephrine | 3 | 2022 | 209 | 0.630 |
Why?
| | Optogenetics | 5 | 2024 | 112 | 0.630 |
Why?
| | Mesencephalon | 5 | 2023 | 66 | 0.630 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2019 | 210 | 0.630 |
Why?
| | Calcium Channels | 4 | 2019 | 164 | 0.620 |
Why?
| | Patch-Clamp Techniques | 11 | 2012 | 277 | 0.580 |
Why?
| | Mice, Inbred C57BL | 13 | 2024 | 5468 | 0.550 |
Why?
| | Receptors, Opioid | 1 | 2016 | 24 | 0.530 |
Why?
| | Dendrites | 3 | 2019 | 98 | 0.520 |
Why?
| | Neuronal Plasticity | 4 | 2024 | 278 | 0.500 |
Why?
| | Cerebral Cortex | 1 | 2019 | 439 | 0.500 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 38 | 0.490 |
Why?
| | Serotonergic Neurons | 1 | 2015 | 28 | 0.490 |
Why?
| | Nerve Growth Factors | 2 | 2008 | 75 | 0.490 |
Why?
| | Raphe Nuclei | 1 | 2015 | 110 | 0.470 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2008 | 204 | 0.460 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2014 | 17 | 0.450 |
Why?
| | Receptors, Nicotinic | 1 | 2016 | 329 | 0.440 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 2 | 2004 | 31 | 0.430 |
Why?
| | Potassium Channels | 3 | 2010 | 149 | 0.430 |
Why?
| | Axons | 3 | 2023 | 193 | 0.420 |
Why?
| | Electric Stimulation | 6 | 2012 | 269 | 0.400 |
Why?
| | Corticotropin-Releasing Hormone | 3 | 2022 | 61 | 0.390 |
Why?
| | Synaptic Vesicles | 2 | 2023 | 42 | 0.360 |
Why?
| | In Vitro Techniques | 7 | 2012 | 1090 | 0.340 |
Why?
| | Mice, Inbred DBA | 5 | 2015 | 191 | 0.320 |
Why?
| | Time Factors | 8 | 2014 | 6545 | 0.320 |
Why?
| | Egtazic Acid | 2 | 2009 | 41 | 0.320 |
Why?
| | Receptors, AMPA | 2 | 2021 | 137 | 0.310 |
Why?
| | Male | 23 | 2024 | 63691 | 0.310 |
Why?
| | Mice, Transgenic | 3 | 2021 | 2135 | 0.300 |
Why?
| | Sodium Channels | 2 | 2010 | 66 | 0.300 |
Why?
| | G Protein-Coupled Inwardly-Rectifying Potassium Channels | 3 | 2016 | 8 | 0.300 |
Why?
| | Organ Culture Techniques | 3 | 2014 | 155 | 0.290 |
Why?
| | Electrochemistry | 4 | 2012 | 79 | 0.280 |
Why?
| | Adrenergic Neurons | 2 | 2018 | 4 | 0.270 |
Why?
| | Receptors, Opioid, kappa | 1 | 2006 | 10 | 0.270 |
Why?
| | Rana catesbeiana | 5 | 2008 | 12 | 0.250 |
Why?
| | Limbic System | 1 | 2006 | 47 | 0.250 |
Why?
| | Narcotics | 1 | 2006 | 45 | 0.250 |
Why?
| | Prefrontal Cortex | 1 | 2008 | 302 | 0.230 |
Why?
| | GABA Antagonists | 3 | 2010 | 32 | 0.230 |
Why?
| | Serotonin | 3 | 2015 | 319 | 0.230 |
Why?
| | Protein Biosynthesis | 2 | 2024 | 406 | 0.220 |
Why?
| | Neural Pathways | 3 | 2012 | 301 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2014 | 0.220 |
Why?
| | Female | 17 | 2022 | 68751 | 0.210 |
Why?
| | HEK293 Cells | 3 | 2024 | 697 | 0.200 |
Why?
| | Membrane Potentials | 4 | 2011 | 291 | 0.200 |
Why?
| | Calcium | 5 | 2012 | 1212 | 0.200 |
Why?
| | Movement Disorders | 1 | 2022 | 52 | 0.190 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 133 | 0.190 |
Why?
| | Basal Ganglia | 1 | 2022 | 53 | 0.190 |
Why?
| | Biophysics | 3 | 2011 | 68 | 0.180 |
Why?
| | Heroin | 1 | 2021 | 30 | 0.180 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2022 | 168 | 0.180 |
Why?
| | Extinction, Psychological | 1 | 2021 | 89 | 0.170 |
Why?
| | Carrier Proteins | 1 | 2024 | 741 | 0.170 |
Why?
| | Rats, Sprague-Dawley | 3 | 2019 | 2403 | 0.170 |
Why?
| | Phosphinic Acids | 2 | 2010 | 9 | 0.170 |
Why?
| | Behavior, Animal | 2 | 2021 | 496 | 0.170 |
Why?
| | Analysis of Variance | 3 | 2012 | 1290 | 0.170 |
Why?
| | Rats | 4 | 2021 | 5485 | 0.160 |
Why?
| | Adaptor Protein Complex 3 | 1 | 2019 | 3 | 0.160 |
Why?
| | Propanolamines | 2 | 2010 | 97 | 0.160 |
Why?
| | Enzyme Inhibitors | 4 | 2008 | 827 | 0.150 |
Why?
| | Exocytosis | 1 | 2019 | 88 | 0.150 |
Why?
| | GTP-Binding Protein gamma Subunits | 1 | 2018 | 5 | 0.150 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2018 | 11 | 0.150 |
Why?
| | Botulinum Toxins | 1 | 2019 | 39 | 0.150 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2018 | 40 | 0.150 |
Why?
| | Single-Domain Antibodies | 1 | 2018 | 6 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2018 | 14 | 0.150 |
Why?
| | Membrane Proteins | 1 | 2024 | 1119 | 0.150 |
Why?
| | Oxidopamine | 1 | 2017 | 13 | 0.140 |
Why?
| | MicroRNAs | 1 | 2024 | 680 | 0.140 |
Why?
| | Chelating Agents | 2 | 2009 | 69 | 0.140 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2016 | 6 | 0.140 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 913 | 0.130 |
Why?
| | Ambenonium Chloride | 1 | 2016 | 1 | 0.130 |
Why?
| | Subthalamic Nucleus | 1 | 2017 | 67 | 0.130 |
Why?
| | Cholinesterase Inhibitors | 1 | 2016 | 30 | 0.130 |
Why?
| | Neurotensin | 1 | 2015 | 12 | 0.120 |
Why?
| | Cells, Cultured | 4 | 2019 | 4102 | 0.120 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4076 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2015 | 1070 | 0.110 |
Why?
| | Drug Interactions | 2 | 2006 | 397 | 0.110 |
Why?
| | Ion Channel Gating | 2 | 2004 | 94 | 0.110 |
Why?
| | Mice, Knockout | 2 | 2018 | 2888 | 0.100 |
Why?
| | Sex Characteristics | 1 | 2018 | 735 | 0.100 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2011 | 96 | 0.100 |
Why?
| | Guinea Pigs | 1 | 2012 | 157 | 0.100 |
Why?
| | Methyl-CpG-Binding Protein 2 | 1 | 2011 | 18 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2015 | 695 | 0.090 |
Why?
| | Species Specificity | 1 | 2012 | 568 | 0.090 |
Why?
| | Iontophoresis | 1 | 2010 | 13 | 0.090 |
Why?
| | Adenosine Triphosphate | 2 | 2003 | 481 | 0.080 |
Why?
| | Calcineurin | 2 | 2024 | 103 | 0.080 |
Why?
| | Picrotoxin | 1 | 2009 | 12 | 0.080 |
Why?
| | Quinpirole | 1 | 2009 | 10 | 0.080 |
Why?
| | Rhodamines | 1 | 2009 | 18 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 84 | 0.080 |
Why?
| | Dizocilpine Maleate | 1 | 2009 | 19 | 0.080 |
Why?
| | Dopamine Agonists | 1 | 2009 | 39 | 0.080 |
Why?
| | Receptors, Dopamine | 2 | 2024 | 16 | 0.080 |
Why?
| | Quinoxalines | 1 | 2009 | 64 | 0.080 |
Why?
| | Calcium Channels, T-Type | 1 | 2010 | 94 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 421 | 0.080 |
Why?
| | Anxiety | 1 | 2015 | 976 | 0.070 |
Why?
| | Humans | 9 | 2024 | 129687 | 0.070 |
Why?
| | Phorbol Esters | 1 | 2008 | 15 | 0.070 |
Why?
| | rap1 GTP-Binding Proteins | 1 | 2008 | 4 | 0.070 |
Why?
| | Receptors, Presynaptic | 1 | 2007 | 8 | 0.070 |
Why?
| | Electric Conductivity | 2 | 2004 | 94 | 0.070 |
Why?
| | Sulpiride | 2 | 2022 | 5 | 0.070 |
Why?
| | Indoles | 1 | 2010 | 386 | 0.070 |
Why?
| | Synaptic Membranes | 1 | 2006 | 17 | 0.070 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2007 | 119 | 0.070 |
Why?
| | Organic Chemicals | 1 | 2008 | 123 | 0.070 |
Why?
| | Temperature | 1 | 2009 | 635 | 0.070 |
Why?
| | Bicuculline | 1 | 2006 | 21 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2008 | 312 | 0.060 |
Why?
| | Biotin | 1 | 2006 | 23 | 0.060 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 28 | 0.060 |
Why?
| | Microinjections | 1 | 2006 | 79 | 0.060 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2006 | 71 | 0.060 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2006 | 133 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1690 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2024 | 2545 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 318 | 0.060 |
Why?
| | Dialysis | 1 | 2004 | 18 | 0.060 |
Why?
| | Naloxone | 1 | 2006 | 112 | 0.060 |
Why?
| | Photometry | 1 | 2024 | 4 | 0.060 |
Why?
| | Intracellular Space | 1 | 2004 | 69 | 0.060 |
Why?
| | Amygdala | 1 | 2006 | 192 | 0.060 |
Why?
| | Analgesics | 1 | 2006 | 190 | 0.060 |
Why?
| | Reaction Time | 1 | 2006 | 411 | 0.060 |
Why?
| | Narcotic Antagonists | 1 | 2006 | 164 | 0.060 |
Why?
| | Allosteric Regulation | 1 | 2024 | 94 | 0.060 |
Why?
| | NFATC Transcription Factors | 1 | 2024 | 86 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2024 | 2702 | 0.060 |
Why?
| | Vesicular Monoamine Transport Proteins | 1 | 2023 | 5 | 0.050 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2003 | 9 | 0.050 |
Why?
| | Denervation | 1 | 2003 | 22 | 0.050 |
Why?
| | 1-Phosphatidylinositol 4-Kinase | 1 | 2003 | 3 | 0.050 |
Why?
| | Calcium Channels, N-Type | 1 | 2003 | 10 | 0.050 |
Why?
| | KCNQ3 Potassium Channel | 1 | 2003 | 3 | 0.050 |
Why?
| | Receptors, LHRH | 1 | 2003 | 14 | 0.050 |
Why?
| | Muscarinic Agonists | 1 | 2003 | 16 | 0.050 |
Why?
| | Receptors, GABA-A | 1 | 2024 | 125 | 0.050 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2003 | 9 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2003 | 45 | 0.050 |
Why?
| | Recurrence | 2 | 2021 | 1012 | 0.050 |
Why?
| | Aluminum | 1 | 2003 | 39 | 0.050 |
Why?
| | Heparin | 1 | 2004 | 254 | 0.050 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2003 | 50 | 0.050 |
Why?
| | COS Cells | 1 | 2003 | 186 | 0.050 |
Why?
| | Androstadienes | 1 | 2003 | 106 | 0.050 |
Why?
| | Hyperkinesis | 1 | 2022 | 17 | 0.050 |
Why?
| | Histone Deacetylases | 1 | 2024 | 212 | 0.050 |
Why?
| | Long-Term Potentiation | 1 | 2024 | 192 | 0.050 |
Why?
| | Type C Phospholipases | 1 | 2002 | 72 | 0.050 |
Why?
| | Calcium Channels, L-Type | 1 | 2003 | 117 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2833 | 0.050 |
Why?
| | Sympathetic Nervous System | 1 | 2002 | 174 | 0.050 |
Why?
| | Antibodies | 1 | 2003 | 399 | 0.040 |
Why?
| | Self Administration | 1 | 2021 | 122 | 0.040 |
Why?
| | Gait | 1 | 2022 | 280 | 0.040 |
Why?
| | Dopamine Antagonists | 2 | 2011 | 23 | 0.040 |
Why?
| | Vesicle-Associated Membrane Protein 2 | 1 | 2019 | 15 | 0.040 |
Why?
| | Protein Binding | 2 | 2018 | 2122 | 0.040 |
Why?
| | Cryptochromes | 1 | 2019 | 23 | 0.040 |
Why?
| | SNARE Proteins | 1 | 2019 | 39 | 0.040 |
Why?
| | Electrophysiology | 2 | 2010 | 213 | 0.040 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2018 | 2 | 0.040 |
Why?
| | Norepinephrine Plasma Membrane Transport Proteins | 1 | 2018 | 5 | 0.040 |
Why?
| | Arabidopsis Proteins | 1 | 2019 | 68 | 0.040 |
Why?
| | Gene Expression | 1 | 2003 | 1465 | 0.040 |
Why?
| | Guanosine Triphosphate | 1 | 2018 | 92 | 0.040 |
Why?
| | Dimerization | 1 | 2018 | 193 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 235 | 0.030 |
Why?
| | Ribosomes | 1 | 2018 | 165 | 0.030 |
Why?
| | Light | 1 | 2019 | 363 | 0.030 |
Why?
| | Receptors, Neurotensin | 1 | 2015 | 11 | 0.030 |
Why?
| | Protein Kinase C | 2 | 2010 | 262 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1310 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 2019 | 296 | 0.030 |
Why?
| | Binding Sites | 1 | 2018 | 1251 | 0.030 |
Why?
| | Presynaptic Terminals | 1 | 2015 | 84 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 872 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1416 | 0.020 |
Why?
| | Radioligand Assay | 1 | 2011 | 48 | 0.020 |
Why?
| | Tritium | 1 | 2011 | 75 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3705 | 0.020 |
Why?
| | Neural Conduction | 1 | 2011 | 83 | 0.020 |
Why?
| | Electrochemical Techniques | 1 | 2011 | 48 | 0.020 |
Why?
| | Cochlear Nucleus | 1 | 2010 | 5 | 0.020 |
Why?
| | Receptors, Dopamine D3 | 1 | 2010 | 4 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2010 | 53 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 203 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2010 | 111 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3084 | 0.020 |
Why?
| | Receptors, GABA-B | 1 | 2009 | 9 | 0.020 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2009 | 27 | 0.020 |
Why?
| | Restraint, Physical | 1 | 2009 | 67 | 0.020 |
Why?
| | Colforsin | 1 | 2007 | 50 | 0.020 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 154 | 0.020 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 55 | 0.020 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2009 | 176 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 1973 | 0.020 |
Why?
| | Age Factors | 1 | 2011 | 3153 | 0.010 |
Why?
| | Phenanthridines | 1 | 2002 | 7 | 0.010 |
Why?
| | Benzophenanthridines | 1 | 2002 | 10 | 0.010 |
Why?
| | Thapsigargin | 1 | 2002 | 19 | 0.010 |
Why?
| | Estrenes | 1 | 2002 | 16 | 0.010 |
Why?
| | Culture Techniques | 1 | 2002 | 81 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2002 | 31 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2002 | 31 | 0.010 |
Why?
| | Alkaloids | 1 | 2002 | 28 | 0.010 |
Why?
| | Pyrrolidinones | 1 | 2002 | 29 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2002 | 83 | 0.010 |
Why?
| | ras Proteins | 1 | 2002 | 143 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 216 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2009 | 1022 | 0.010 |
Why?
|
|
Ford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|